Back to Search
Start Over
Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.
- Source :
-
Leukemia Research . Jan2019, Vol. 76, p87-93. 7p. - Publication Year :
- 2019
-
Abstract
- Highlights • 57.5% of total colonies were compound mutant colonies. • 89.3% of compound mutant colonies had at least one major mutation. • 13 patients had low-level allosteric site mutations throughout various TKI therapies. • Low-level mutations detected only by subcloning sequencing had clinical significance. • Higher sensitive assay should be used in case of TKI failure and multiple mutations. Abstract To analyze the pattern of multiple mutations detected by Sanger sequencing (SS), we performed subcloning sequencing using 218 samples from 45 patients with tyrosine kinase inhibitor resistant chronic myeloid leukemia. At the first time of multiple mutation detection by SS (baseline), a total of 19 major mutations from 45 samples were detected; these mutations were found in the following order: T315I (68.9%), E255 K (33.3%), Y253H (13.3%), G250E (13.3%), and F317 L (11.1%). Subcloning sequencing of 900 baseline colonies identified 556 different mutant types, and 791 among the 900 were colonies with major mutations (87.9%). The mutations were found in the following order: T315I (36.4%), E255 K (16.2%), Y253H (7.0%), G250E (6.7%), M351 T (6.6%), and E255 V (5.3%). In subcloning sequencing with 4357 colonies of 218 serial samples, 2506 colonies (57.5%) had compound mutations, among which 2238 colonies (89.3%) had at least one major mutation. The median number of mutations in compound mutant colonies was 2 (range, 2–7), and most were double (52.9%) or triple (28.7%) mutations. Additionally, some mutations in allosteric binding sites were detected as low level mutation in 13 patients. With the available retrospective samples before baseline, subcloning sequencing identified low-level mutations of various frequencies (median, 10%) to be major mutations in 20 patients. Thus, compound mutations involving T315I and P-loop mutations were the major components of multiple mutations, and some low-level mutations with potential clinical significance were detected by subcloning sequencing. Hence, more sensitive sequencing assays are needed in patients with multiple mutations. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01452126
- Volume :
- 76
- Database :
- Academic Search Index
- Journal :
- Leukemia Research
- Publication Type :
- Academic Journal
- Accession number :
- 133720691
- Full Text :
- https://doi.org/10.1016/j.leukres.2018.10.019